Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Lynda M. Vrooman, Yael Flamand, Melissa A. Burns, Victoria B. Koch, Sarah M. Cronholm, Sarah K. Hunt, Peter D. Cole, Lisa M. Gennarini, Marian H. Harris, Nobuko Hijiya, Justine M. Kahn, Kara M. Kelly, Bruno Michon, Andrew E. Place, Thai Hoa Tran, Jennifer J.G. Welch, Stephen E. Sallan, Lewis B. Silverman

Blood (2024) 144 (Supplement 1): 311.

https://doi.org/10.1182/blood-2024-208605

Published: 2024

Journal Articles

Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

Melissa A. Burns, Yael Flamand, Lynda M. Vrooman, Victoria B. Koch, Yves Theoret, Sarah M. Cronholm, Sarah K. Hunt, Peter D. Cole, Lisa M. Gennarini, Nobuko Hijiya, Justine M. Kahn, Kara M. Kelly, Bruno Michon, Donna S. Neuberg, Andrew E. Place, Thai Hoa Tran, Jennifer J.G. Welch, Stephen E. Sallan, Lewis B. Silverman

Blood (2024) 144 (Supplement 1): 307.

https://doi.org/10.1182/blood-2024-207273

Published: 2024

Journal Articles

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Hari S. Raman, Shai Shimony, Yannis K. Valtis, Yael Flamand, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna S. Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin

Blood (2023) 142 (Supplement 1): 1456.

https://doi.org/10.1182/blood-2023-178353

Published: 2023

Journal Articles

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Jacqueline S. Garcia, Eric S. Winer, Ilene Galinsky, Julie Bergeron, Julie Asch, Matthew D. Seftel, Richard M Stone, Marlise R. Luskin, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 4238.

https://doi.org/10.1182/blood-2023-181014

Published: 2023

Journal Articles

Adolescent and Young Adults with ALL Who Complete Therapy on DFCI Consortium ALL Trials Have Excellent Long-Term Overall Survival

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Richard M. Stone, Daniel J DeAngelo, Marlise R. Luskin

Blood (2022) 140 (Supplement 1): 8901–8903.

https://doi.org/10.1182/blood-2022-159286

Published: 2022

Journal Articles

Body Mass Index Effect on Survival and Toxicities Differs between Age Groups Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials

Shai Shimony, Yael Flamand, Yannis K. Valtis, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Richard M. Stone, Martha Wadleigh, Donna S. Neuberg, Daniel J DeAngelo, Marlise R. Luskin

Blood (2022) 140 (Supplement 1): 3164–3165.

https://doi.org/10.1182/blood-2022-158348

Published: 2022

Journal Articles

Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium

Blood (2021) 138 (Supplement 1): 3396.

https://doi.org/10.1182/blood-2021-151313

Published: 2021

Journal Articles

Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001

Lynda M. Vrooman, MD, Yael Flamand, MS, Victoria Koch, BS, Melissa A. Burns, MD, Sarah M. Cronholm, BA, Sarah K. Hunt, BS, MPH, Peter D. Cole, MD, Lisa M. Gennarini, MD, Justine M. Kahn, MDMSc, Kara M. Kelly, MD, Bruno Michon, MD FRCPC, Donna S. Neuberg, ScD, Andrew E. Place, MDPhD, Thai Hoa Tran, MD, Jennifer J.G. Welch, MD, Kristen E. Stevenson, MS, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-138840

Published: 2020

Journal Articles

Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort

Qianqian Zhu, PhD, Song Yao, PhD, Peter D Cole, MD, Justine M. Kahn, MD MS, Marian H. Harris, MD PhD, Emily Schiller, MS, Uma Athale, MDMBBS,MSc, Luis A. Clavell, MD, Caroline Laverdiere, MD FRCPC, Jean-Marie Leclerc, MDFRCPC, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Jennifer J.G. Welch, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD, Kara M. Kelly, MD

Blood (2019) 134 (Supplement_1): 3811.

https://doi.org/10.1182/blood-2019-126814

Published: 2019

Journal Articles

PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL

Blood (2018) 132 (Supplement 1): 889.

https://doi.org/10.1182/blood-2018-99-113518

Published: 2018

Journal Articles

The Fanconi Pathway in Pediatric T-Cell Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 2722.

https://doi.org/10.1182/blood.V130.Suppl_1.2722.2722

Published: 2017

Journal Articles

Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Kara M. Kelly, MD, Elena Ladas, PhD, Traci M. Blonquist, MS, Kristen E. Stevenson, MS, Meiko Lin, MA, Peter D Cole, MD, Manuela Orjuela, MD ScM, Uma Athale, Luis A. Clavell, MD, Caroline Laverdière, MDFRCPC, Jean-Marie Leclerc, MDFRCPC, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Barbara L Asselin, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2017) 130 (Supplement 1): 2549.

https://doi.org/10.1182/blood.V130.Suppl_1.2549.2549

Published: 2017

Journal Articles

Hedgehog Pathway Mutations Drive Oncogenic Transformation in High-Risk T-Cell Acute Lymphoblastic Leukemia

Melissa A. Burns, MD, Zi Wei Liao, Gayle P. Pouliot, MD PhD, Kristen E. Stevenson, MS, Donna S. Neuberg, ScD, Aaron R. Thorner, PhD, Matthew D. Ducar, MS, Emily A. Silverman, Stephen P. Hunger, MD, Mignon L. Loh, MD, Stuart S. Winter, MD, Kimberly P. Dunsmore, MD, Brent Wood, MDPhD, Meenakshi Devidas, PhD, Marian H. Harris, MD PhD, Lewis B. Silverman, MD, Stephen E. Sallan, MD, Alejandro Gutierrez, MD

Blood (2017) 130 (Supplement 1): 367.

https://doi.org/10.1182/blood.V130.Suppl_1.367.367

Published: 2017

Journal Articles

Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Uma H. Athale, MD, M.Sc., Traci M. Blonquist, MS, Kristen E. Stevenson, MS, Menachem Spira, Peter D. Cole, MD, Barbara L Asselin, MD, Luis A. Clavell, MD, Kara M. Kelly, MD, Caroline Laverdière, MDFRCPC, Jean-Marie Leclerc, MD, Bruno Michon, MD, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Marian H. Harris, MD PhD, Donna S. Neuberg, ScD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2017) 130 (Supplement 1): 1278.

https://doi.org/10.1182/blood.V130.Suppl_1.1278.1278

Published: 2017

Journal Articles

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Blood (2016) 128 (22): 175.

https://doi.org/10.1182/blood.V128.22.175.175

Published: 2016

Journal Articles

Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium

Blood (2016) 128 (22): 1729.

https://doi.org/10.1182/blood.V128.22.1729.1729

Published: 2016

Journal Articles

PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 604.

https://doi.org/10.1182/blood.V128.22.604.604

Published: 2016

Journal Articles

Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001

Uma H. Athale, MD, M.Sc., Maneka Puligandla, MS, Kristen E. Stevenson, MS, Barbara L. Asselin, MD, Luis A. Clavell, MD, Peter D. Cole, MD, Kara M. Kelly, MD, Caroline Laverdiere, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Marian H. Harris, MD PhD, Donna S. Neuberg, Sc.D., Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2016) 128 (22): 761.

https://doi.org/10.1182/blood.V128.22.761.761

Published: 2016

Journal Articles

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Daniel J. DeAngelo, MD PhD, Kristen Stevenson, MS, Donna S Neuberg, ScD, Lewis B. Silverman, MD, Karen K. Ballen, MD, Julie D. Asch, MD, Yasser Abou Mourad, MD, Kristjan Paulson, MD FRCPC, Matthew D. Seftel, MBChB, FRCP(C), MRCP, David Avigan, MD, Julie Bergeron, MD, Stephen Couban, MD, William Blum, MD, John Storring, MD, Martha Wadleigh, MD, David P. Steensma, MD, Jeffrey Supko, PhD, Stephen E. Sallan, MD, Richard M. Stone, MD

Blood (2015) 126 (23): 80.

https://doi.org/10.1182/blood.V126.23.80.80

Published: 2015

Journal Articles

Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001

Peter D. Cole, MD, Traci M. Blonquist, MS, Veena Vijayanathan, PhD, Donna S. Neuberg, Sc.D., Lynda M. Vrooman, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD, Yaron Finkelstein, MD

Blood (2015) 126 (23): 251.

https://doi.org/10.1182/blood.V126.23.251.251

Published: 2015

NARROW

Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Adolescent and Young Adults with ALL Who Complete Therapy on DFCI Consortium ALL Trials Have Excellent Long-Term Overall Survival

Body Mass Index Effect on Survival and Toxicities Differs between Age Groups Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials

Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium

Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001

Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort

PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL

The Fanconi Pathway in Pediatric T-Cell Acute Lymphoblastic Leukemia

Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Hedgehog Pathway Mutations Drive Oncogenic Transformation in High-Risk T-Cell Acute Lymphoblastic Leukemia

Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium

PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia

Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only